EARLY ACCESS – LIMITED COHORT 2026
Adherent cells don’t scale.
Until now.
COHORT SEATS
< 3 available
OPEN UNTIL
Q4 2026
EXEMPLARY CELL TYPES
iPSC • MSC • Macrophages
SURFACE AREA
up to 10,000 cm²
SHEAR STRESS
minimized
ARCHITECTURE
closed system
CULTIVATION
dynamic adherent
THE BOTTLENECK
2D doesn’t scale. Suspension reactors weren’t built for adherent cells.
01 – LIMITED SURFACE
T-flasks and stacks max out
Manual handling, contamination risk, and operator-bound throughput break the moment your process moves from preclinical to clinical batches.
02 – INCREASING COMPLEXITY
Microcarriers add complexity
Shear stress, harvest losses, and batch-to-batch transfer headaches turn a scale-up project into a multi-quarter optimization cycle.
03 – CHANGING BIOLOGY
Suspension bioreactors don’t fit
Stirred tanks were designed for cells that float. Adherent biology behaves differently and most reactors can’t accommodate that.
04 – COST INTENSIVE
Time-to-clinic is the cost
Every month spent re-engineering manufacturing is a month your therapy isn’t reaching patients. Process bottlenecks delay everything downstream.
THE SOLUTION
Meet Archimedes® One — dynamic adherent bioreactor
Green Elephant”s efficient expansion solution for adherent cell manufacturing. Engineered from first principles for iPSC, MSC, and macrophage workflows. No microcarriers. No 2D-to-3D rebuild. Scale the cells you already have.
Adherent expansion at bioreactor scale
Manual handling, contamination risk, and operator-bound throughput break the moment your process moves from preclinical to clinical batches.
10,000 cm² growth surface/unit
Reduced shear stress
Geometry-driven flow path keeps cells within physiological shear limits. Sensitive cells stay viable and maintain phenotype across long expansion runs.
1 homogeneous culture
Gentle, high-recovery harvest
Detachment protocol designed for primary and stem cell biology. Phenotype preserved, harvest yields predictable.
>90% recovery in validated protocols
Closed-system architecture
Single-use, closed format from seed to harvest. GMP-aligned design that fits cleanroom workflows without bolt-on engineering.
100% closed, single-use flow path
WHAT YOU GET
Early Access partners ship faster. And pay less to do it.
01
Pilot pricing
Early Access partners lock in cohort pricing that won’t be offered post-launch. Designed to make pilot deployment commercially obvious.
02
Cultivation data packages
Cultivation data that does real work in your regulatory programme. Protocol establishment, pre-clinical generation, and manufacturing change support — structured to accelerate your path to clinical approval.
03
Pre-launch deployment
Receive Archimedes® One units months before general availability. Run your process on the platform while competitors are still on a waitlist.
3
Slots in the Early Access cohort available.
IS THIS FOR YOU?
We’re looking for the right fit. Not the most applicants.
You’re a fit if
- You develop or manufacture iPSC, MSC, or macrophage-based products
- You have a concrete scale-up need within the next 6 to 12 months
- Your pipeline is at preclinical-late or clinical stage
- You operate as a CGT developer or a CDMO with adherent capacity
- You have process development resources to evaluate the platform
- You’re open to a working partnership with our scientific team
This isn’t for you if
- You work exclusively with suspension cells
- You’re researching new platforms for a 2028+ horizon
- You don’t have a defined process or pipeline yet
- You can’t allocate PD or manufacturing time to evaluation
- You’re looking for a research-only or single-experiment unit
HOW IT WORKS
From application to first run in four steps.
APPLY
